Cargando…
Analysis of the US Safety Data for Edaravone (Radicava(®)) From the Third Year After Launch
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neuromuscular disease with no curative therapies. Edaravone (Radicava(®)) (Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan), approved in the United States (US) for ALS in adults in 2017, was shown in a clinical trial to sl...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433633/ https://www.ncbi.nlm.nih.gov/pubmed/35723868 http://dx.doi.org/10.1007/s40268-022-00391-6 |